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Abstract 
Background: Bone loss associated with low oestrogen levels in postmenopausal women, and 
androgen deprivation therapy in men with hormone-sensitive prostate cancer, leads to an increased 
incidence of fractures.  Denosumab has been shown to increase bone mineral density in these two 
conditions. Objectives/Methods: The objective of this evaluation is to review the clinical trials that 
have studied clinical endpoints in these conditions.  Results: FREEDOM (Fracture Reduction 
Evaluation of Denosumab in Osteoporosis Every 6 Months) was an International Phase III clinical 
trial, which measured the clinical endpoints with denosumab in postmenopausal women with 
osteoporosis.   At 36 months, new vertebral fractures had occurred in 7.2% of subjects in the placebo 
group and this was lowered to 2.3% of subjects treated with denosumab.  HALT (Denosumab 
Hormone Ablation Bone Loss Trial) studied the clinical endpoints in men with non-metastatic prostate 
cancer receiving androgen-deprivation therapy.  The incidence of vertebral fractures was significantly 
lower in the denosumab group (1.5%) than in the placebo group (3.9%).  The incidence of adverse 
effects with denosumab in both clinical trials was low. Conclusions Denosumab reduces the incidence 
of fractures in postmenopausal women with osteoporosis and in men with non-metastatic prostate 
cancer receiving androgen-deprivation therapy.  Denosumab is well tolerated.   
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1. Introduction 
Denosumab is a new treatment for bone loss.  It is a human monoclonal antibody to the receptor 
activator of nuclear factor-κB ligand (RANKL).  RANKL is a cytokine that has an important role in the 
formation, function and survival of osteoclasts.  Denosumab prevents the interaction of RANKL with 
its receptor RANK on the osteoclasts, which leads to the inhibition of osteoclasts-mediated bone 
resorption.  Thus, denosumab has the potential to prevent bone loss in a variety of conditions 
associated with excessive bone loss, and two of the recent studies are considered in this evaluation.  
Firstly, a trial showing that denosumab reduces the incidence of fractures in postmenopausal women 
with osteoporosis [1].  Secondly, a trial in men receiving androgen-deprivation therapy for prostate 
cancer, which also shows that denosumab decreased the incidence of fractures [2]. 
2. Denosumab in osteoporosis 
Osteoporosis affects > 10 million people in the US, at an annual cost of US$17 billion [3].  It is 
associated with stooped posture, loss of height, back pain, and fractures.  Nearly 2 million hip 
fractures occur each year in the US as a result of osteoporosis [3].  After hospital discharge, one in 
five people die within one year of hip fracture, and one in three require nursing home placement [3].  
Low levels of oestrogens are a major risk factor for osteoporosis, and consequently, postmenopausal 
women are at increased risk. 
Phase II clinical trials have shown that denosumab increases bone mineral density and decreases 
bone turnover in postmenopausal women with osteoporosis [4,5,6].  Although not set up to determine 
clinical endpoints, one of the trials showing denosumab increased bone mineral density, also showed 
that the incidence of clinical fractures was lower in the denosumab group (1%) than in the placebo 
group (4%) [5].  However, another bone mineral density clinical trial in postmenopausal women, found 
similar levels of clinical fractures with and without denosumab treatment [6].  This emphasized the 
need for a large Phase III clinical trial determining clinical endpoints with denosumab. 
3. Clinical endpoints with denosumab in postmenopausal women with osteoporosis 
 
3.1 Methods and results 
FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) was an 
International Phase III clinical trial, which measured the clinical endpoints with denosumab [1], and 
the methods and results of this trial are précised in this section.  FREEDOM enrolled women aged 60-
90 years with a bone mineral density T score of less than -2.5 at the lumbar spine or total hip.  
Women were excluded if they had recently taken other drugs for osteoporosis that may have ongoing 
effects e.g. bisphosphonates.   
The 7868 enrolled women had a mean age of 72 years, with a lumbar spine T score of -2.8.  Most of 
them (73%) did not have a prevalent vertebral fracture. 
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All women received 1000 mg of calcium and vitamin D supplementation depending on their plasma 
levels of 25-hydroxyvitamin D.  Thus, if plasma levels of 25-hydroxyvitamin D were in the range of 12-
20 ng/ml, the women were given at least 800 IU of vitamin D daily, and those with a baseline level 
above 20 mg/ml, 400 IU of vitamin D daily.  The women were randomised to receive subcutaneous 
injects of denosumab 60 mg or placebo at the study sites every 6 months for 36 months. 
The primary endpoint was a new vertebral fracture, and these were assessed from lateral spinal 
radiographs taken annually.  A prevalent fracture was defined as a vertebral body of grade 1 or more, 
and a new vertebral fracture was an increase of at least 1 grade.  At 36 months, new vertebral 
fractures had occurred in 264 of 3691 subjects in the placebo group (7.2%) and this was lowered to 
86 of 3702 in subjects treated with denosumab (2.3%). 
Secondary endpoints included nonvertebral fractures and these occurred in 8.0% of placebo subjects, 
and were reduced to 6.5% with denosumab. Hip fracture occurred less with denosumab (0.7%) than 
with placebo (1.2%). 
With denosumab, the increase in bone mineral density was 9.2% at the lumbar spine and 6.0% at the 
total hip.  At 36 months, denosumab decreased bone absorption (measured as the marker, serum C-
telopeptide) by 72% and decreased the levels of bone formation (measured as the marker, serum 
procollagen type 1 N-terminal propeptide) by 76%. 
The total incidence of adverse and serious adverse events was similar in both groups.  The only 
excess of adverse effects with denosumab was eczema (3.0% with denosumab; 1.7% with placebo), 
flatulence (2.2% versus 1.4%) and cellulitis (1% versus 0.3%). 
3.2 Discussion 
The authors discussed that the reduction of vertebral fractures with denosumab was similar to that 
observed with intravenous zoledronic acid, and greater than that with oral agents for osteoporosis [1].  
4. Denosumab in prostate cancer 
 
Prostate cancer underlies 25% of new cancers and 10% of cancer deaths in the US.  Bone loss in 
prostate cancer may occur prior to treatment and be due to the disease per se, and is also caused by 
the orchiectomy or androgen deprivation therapy (e.g. gonadotrophin-releasing hormone receptor 
agonist) used to treat prostate cancer.  With these agonists, it is probably the oestrogen deficiency 
rather than the low levels of testosterone than underlies the bone loss [7]. 
 
Denosumab has been shown to prevent bone loss in postmenopausal women (discussed previously).  
Denosumab has also been shown to increase bone mineral density in women with nonmetastatic 
breast cancer being treated with adjuvant aromatase inhibitors to reduce levels of oestrogens.  This 
suggests that denosumab may also be useful at preventing the bone loss associated with the 
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oestrogen deficiency associated with orchiectomy or androgen deprivation therapy in nonmetastatic 
prostate cancer. 
 
5. Clinical endpoints with denosumab in men receiving androgen-deprivation therapy for 
prostate cancer 
 
The methods and results of the HALT (Denosumab Hormone Ablation Bone Loss Trial) showing 
denosumab prevents bone loss and the resulting fractures in subjects with non-metastatic prostate 
cancer [2] are summarised in this section.  The clinical trial enrolled 1468 men taking androgen-
deprivation therapy for non-metastatic, hormone-sensitive prostate cancer.  In addition, the men had 
to have a low bone mineral density, which was defined at a T score at the lumbar spine, total hip, of 
femoral neck of less than -1.0, or a history of an osteoporotic fracture.  Men with recent exposure to 
the bisphosphonates were excluded.    
 
The men enrolled had an average age of ~75 years old, were predominantly white (~83%, 11% 
Hispanic).  Only about 15% of the mean has a T score below -2.5 at any site, indicating osteoporosis.  
The mean T scores were -0.55, -0.9, and -1.4 at the lumbar spine, total hip and femoral neck, 
respectively.  The subjects were randomised to receive denosumab 60 mg subcutaneously or placebo 
at 6 month intervals. 
 
The primary endpoint was the percent change in the baseline bone mineral density of the lumbar 
spine at 24 months.  Bone mineral density decreased in the placebo group while increasing in the 
denosumab group, so that the difference at 24 months was 6.7, 4.8, and 3.9 percentage points at the 
lumbar spine, total hip and femoral neck, respectively.  One of the secondary endpoints was the 
percentage change after 36 months, and this showed continuing increases in bone mineral density 
with denosumab. 
 
Important secondary endpoints were the incidence of any newly diagnosed fracture and of vertebral 
fractures at 36 months.  The incidence of any newly diagnosed fracture was lower with denosumab 
(5.2%) than in the placebo group (7.2%) but this difference was not significant.  The incidence of 
vertebral fractures was significantly lower in the denosumab group (1.5%; 10 of 678 subjects) than in 
the placebo group (3.9%, 26 of 673 subjects).  The benefit with denosumab was significant at 12 
months (0.3 vs 1.9%). 
 
The markers of bone turnover, serum levels of C-telopeptide, procollagen type I N-terminal peptide 
and TRAP-5b were decreased at 36 months from baseline by 13, 18 and 8% in the placebo group, 
and these decreases were greater at 45, 61 and 33%, respectively, in the denosumab group. 
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Death rates were similar in both groups.  Adverse event profiles were similar in the placebo and 
denosumab groups.  Cataracts developed in more subjects receiving denosumab (4.7%) than 
placebo (1.2%). 
 
6. Expert opinion 
 
6.1 Denosumab in postmenopausal women with osteoporosis 
6.1.1 Bone mineral density score 
FREEDOM enrolled postmenopausal women with a T score of -2.5.  The Phase II trials with 
denosumab enrolled women with a T score of -1.8 [4,5,6].  Thus, the Phase III trial was in more 
serious osteoporosis than the Phase II clinical trials with denosumab.  Consequently, further Phase III 
trials are need in postmenopausal women with less severe osteoporosis to determine whether 
denosumab is also effective in reducing fractures in this group. 
6.1.2 Comparison with zoledronic acid 
The intravenous bisphosphonate zoledronic acid has been shown to decrease the incidence of 
fractures in postmenopausal women with osteoporosis from 10.9% in the placebo group to 3.3% in 
the zoledronic acid group after 3 years [8].  The recent study of denosumab in the same population 
has shown a reduction from 7.2% in the placebo group to 2.3% in the denosumab group [1].  Thus, 
zoledronic acid and denosumab seem to have a similar ability to reduce fractures in postmenopausal 
women with osteoporosis.  Consequently, the choice between zoledronic acid and denosumab in 
these women may be on the basis of safety. 
Both zoledronic acid and denosumab have been shown to be well tolerated in the treatment of 
postmenopausal osteoporosis.  Zoledronic acid injection is associated with small excess of pyrexia, 
myalgia, influenza-like symptoms, headache, and arthralgia [8] whereas denosumab caused a small 
excess in eczema, flatulence, and cellulitis [1]. 
Only a direct comparator trial can provide a true comparison between zoledronic acid and denosumab 
in the treatment of postmenopausal osteoporosis.  Such a trial should be undertaken.  Also, as 
denosumab and zoledronic acid have different mechanisms, it is possible that they may have additive 
effects on bone mineral density and decreasing the incidence of fractures.  Thus, the comparator 
study should also include a group combining zoledronic acid and denosumab. 
6.1.3 Comparison with parathyroid hormone preparations 
Parathyroid hormone preparations (teriparatide [9] and human parathyroid hormone, 1-84 [10]) have a 
similar ability to zoledronic acid and denosumab to prevent fractures.  Thus, it is of interest to know if 
there are advantages and disadvantaged to these treatments.  Also, as parathyroid hormone 
preparations have a different mechanism to denosumab i.e. parathyroid hormone preparation 
promote bone formation rather than inhibiting bone reabsorption like denosumab, these two 
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approaches may have additive effects in osteoporosis.  A clinical trial is underway comparing 
denosumab, teriparatide or both for the postmenopausal osteoporosis [11], and this trial will answer 
these important questions. 
6.2 Denosumab in men receiving androgen-deprivation therapy for prostate cancer 
 
6.2.1 Comparison with zoledronic for bone loss in prostate cancer 
Zoledronic acid is the most potent bisphosphonate and has been shown to increase bone mineral 
density in subjects with non-metastatic prostate cancer.  After 12 months, the bone mineral density at 
the lumbar spine was increased by 7.8 percentage points by zoledronic acid [12].  This is greater than 
the 6.7 percentage points observed with denosumab after 24 months [1].  The effect of zoledronic 
acid on the incidence of fractures in men with non-metastatic prostate cancer has not been 
determined.  However, if the reduction in bone mineral density is a good marker of the reduction in 
fractures, zoledronic acid may be more potent than denosumab in inhibiting fracture.   This could be 
tested in a head-to-head trial of zoledronic acid and denosumab in subjects with non-metastatic 
prostate cancer. 
 
Recently, zoledronic acid has been shown to have anti-cancer activity in premenopausal women with 
breast cancer [13].  If this anti-cancer activity is observed with zoledronic acid in other cancers, it will 
probably give zoledronic acid an advantage over denosumab.  The study evaluated was of the effect 
of denosumab on bone mineral density and fractures in men with non-metastatic prostate cancer, and 
was not set up to determine any anti-cancer effects of denosumab.  Metastasis to the bone developed 
in 10 subjects in the placebo group (1.4%) compared to 3 subjects in the denosumab group (0.4%).  
Comparisons of zoledronic acid and denosumab in subjects with non-metastatic prostate cancer 
should consider not only the incidence of fractures, but also any anti-cancer activity of these agents. 
 
6.2.2 Ongoing clinical trials with denosumab in prostate cancer 
Denosumab is currently being compared to zoledronic acid in men with bone metastases associated 
with hormone-refractory prostate cancer [14].  The primary endpoint for this study is the time to first 
skeletal related event [14].  The anti-cancer of the two drugs should also be considered in this study. 
 
One unexpected finding in the study of denosumab in non-metastatic prostate cancer was an 
increased incidence of cataracts [2].  A study to evaluate new or worsening lens opacifications in 
subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen-
deprivation therapy is underway [15].  Given the increased incidence of cataracts observed, this is an 
important safety study. 
 
6.3 Conclusions 
Recent clinical trials have shown that denosumab reduces the incidence of fractures in 
postmenopausal women with osteoporosis and in men with non-metastatic prostate cancer receiving 
androgen-deprivation therapy.  Denosumab is well tolerated.  Comparator and combination trials with 
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zoledronic acid and other agents for bone loss are necessary to determine the relative efficacy and 
safety of the agents, and to determine whether an additive effect can be achieved with combination 
therapy.   
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